A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Active, not recruiting · NCT03653507 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 3 | 2026-09-28 | NCT03653507 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Global Development, Inc. | 43 |
165 results · Page 1 of 7
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Houston Methodist Cancer Center and Institute of Academic Medicine - Oncology | Houston | United States | 1 |
| Montefiore Medical Center (MMC) | The Bronx | United States | 1 |
| New Mexico Oncology Hematology | Albuquerque | United States | 2 |
| Ochsner Clinic CCOP | New Orleans | United States | 1 |
| Pacific Cancer Care | Monterey | United States | 13 |
| Parkland Hospital | Dallas | United States | 2 |
| Prisma Health Cancer Institute | Boiling Springs | United States | 2 |
| Site AR54001 | San Miguel de Tucumán | Argentina | 1 |
| Site AR54003 | Viedma | Argentina | 1 |
| Site AR54004 | San Miguel de Tucumán | Argentina | 1 |
| Site AR54006 | Pergamino | Argentina | 1 |
| Site AR54009 | Buenos Aires | Argentina | 1 |
| Site CA15002 | Rimouski | Canada | 1 |
| Site CA15003 | Chicoutimi | Canada | 1 |
| Site CA15004 | Calgary | Canada | 1 |
| Site CN86001 | Guangzhou | China | 2 |
| Site CN86002 | Changchun | China | 1 |
| Site CN86004 | Wuhan | China | 1 |
| Site CN86005 | Wuhan | China | 1 |
| Site CN86007 | Hangzhou | China | 1 |
| Site CN86009 | Tianjin | China | 1 |
| Site CN86011 | Xuzhou | China | 1 |
| Site CN86012 | Zhengzhou | China | 1 |
| Site CN86013 | Xi'an | China | 1 |
| Site CN86014 | Shanghai | China | 2 |